The study aims to discover risk factors significantly correlated with insulin resistance among adolescents in Taiwan. A total of 339 study subjects were recruited in this cross-sectional study. A self-administered questionnaire and physical examinations including anthropometrics and biochemistry profiles were collected. Insulin resistance was assessed using homeostasis model assessment for insulin resistance (HOMA-IR). Study subjects had a significantly increased risk of IR for those with abnormal level of body mass index (odds ratio [OR] = 3.54; 95% confidence interval [CI] = 1.81-6.91), body fat (OR = 2.71; 95% CI = 1.25-5.88), and waist circumference (OR = 25.04; 95% CI = 2.93-214.14) when compared with those who have normal values. Furthermore, a significantly joint effect of 10.86-fold risk for HOMA-IR abnormality among body fat, body mass index, and systolic blood pressure was observed. The identification of risk factors significantly correlated with IR will be important to prevent metabolic syndrome–related diseases and complications for adolescents in their future life.
BerardinelliWCordeiroJGDe AlbuquerqueDCouceiroA. A new endocrine-metabolic syndrome probably due to a global hyper-function of the somatotrophin. Acta Endocrinol (Copenh). 1953;12:69-80.
2.
PacificoLAnaniaCMartinoF. Management of metabolic syndrome in children and adolescents. Nutr Metab Cardiovasc Dis. 2011;21:455-466.
3.
ZimmetPAlbertiGKaufmanF. International Diabetes Federation Task Force on Epidemiology and Prevention of Diabetes. The metabolic syndrome in children and adolescents. Lancet. 2007;369:2059-2061.
4.
GoodmanEDanielsSRMeigsJBDolanLM. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation. 2007;115:2316-2322.
5.
ChangTYChenJD. Fatty liver and metabolic syndrome in nonabdominally obese Taiwanese adults. Asia Pac J Public Health. 2012;24:472-479.
6.
MalikSWongNDFranklinSS. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250.
7.
FordESGilesWHDietzWH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
8.
MisraAKhuranaL. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008;93:S9-S30.
9.
HwangLCBaiCHChenCJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc. 2006;105:626-635.
10.
DespresJPLamarcheBMauriegeP. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
11.
LinCJLiuJTChangCHNowalkMP. Association of obesity and chronic diseases in Taiwan. Asia Pac J Public Health. 2006;18:8-14.
12.
KeskinMKurtogluSKendirciMAtabekMEYaziciC. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005;115:e500-e503.
OgdenCLLiYFreedmanDSBorrudLGFlegalKM. Smoothed percentage body fat percentiles for U.S. children and adolescents, 1999-2004. Natl Health Stat Report. 2011;(43):1-7.
15.
ChanECChangPYWuTLWuJT. Enzymatic assay of homocysteine on microtiter plates or a TECAN analyzer using crude lysate containing recombinant methionine gamma-lyase. Ann Clin Lab Sci. 2005;35:155-160.
16.
Rogero BlancoMEAlbañil BallesterosMRSánchez MartinMRabanal BasaloAOlivas DomínguezAGarcía LacalleC. Prevalence of insulin resistance in a young adult population. Relationship with weight status. Endocrinol Nutr. 2012;59:98-104.
17.
ReavenG. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am. 2004;33:283-303.
18.
ShimamotoK. Insulin resistance syndrome and hypertension. Hokkaido Igaku Zasshi. 2000;75:9-14.
19.
AndersonEAHoffmanRPBalonTWSinkeyCAMarkAL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87:2246-2252.
20.
WoodsSCPorteDBobbioniE. Insulin: its relationship to the central nervous system and to the control of food intake and body weight. Am J Clin Nutr. 1985;42(5 suppl):1063-1071.
21.
HollenbeckCReavenGM. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance. J Clin Endocrinol Metab. 1987;64:1169-1173.
22.
DeFronzoRAFerranniniE. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
23.
HaffnerSM. Abdominal adiposity and cardiometabolic risk: do we have all the answers?Am J Med. 2007;120(9suppl 1):S10-S16.
ArterburnDECranePKVeenstraDL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164:994-1003.
26.
DespresJPGolayASjostromL. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121-2134.
27.
HuttonBFergussonD. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr. 2004;80:1461-1468.
28.
ScottRWuMSanchezMSteinP. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61: 171-180.
29.
RazIHanefeldMXuL; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
30.
BosiECamisascaRPColloberCRochotteEGarberAJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-895.
